<p>&lt;&lt;insert slide 1; Chapter Title: Click or tap here to enter text.; 00:00 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Ask the Experts: Guidelines and Emerging Treatments for Eosinophilic Esophagitis</strong></p>

<p>&lt;&lt;insert slide 2; Chapter Title: Click or tap here to enter text.; 00:36 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Off-Label Disclaimer</strong></p>

<p>&lt;&lt;insert slide 3; Chapter Title: <strong>Overview</strong>; 00:54 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; EoE Overview<sup>[1]</sup></strong></p>

<p>&#8226;	Eosinophilic esophagitis (EoE) is an allergy-mediated condition caused by an excess of eosinophils in the esophagus</p>

<p>&#8226;	Although EoE symptoms overlap with gastroesophageal reflux disease, they are 2 very different conditions</p>

<p>&lt;&lt;insert slide 4; Chapter Title: Click or tap here to enter text.; 01:52 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Epidemiology of EoE<sup>[2,3]</sup></strong></p>

<p>&#8226;	EoE has a genetic preponderance in white males; it is seen about twice as often in males as in females</p>

<p>&lt;&lt;insert slide 5; Chapter Title: <strong>Symptoms and Diagnosis</strong>; 02:48 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Symptoms of EoE: Children<sup>[4,5]</sup></strong></p>

<p>&#8226;	EoE symptoms in children are often nonspecific</p>

<p>&lt;&lt;insert slide 6; Chapter Title: Click or tap here to enter text.; 03:18 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Clinical Symptoms of EoE: Adolescents and Adults<sup>[5,6]</sup></strong></p>

<p>&#8226;	In adults, the primary EoE symptom is dysphagia, or trouble swallowing</p>

<p>&#8226;	Some patients will avoid hard foods like crusty bread and will eat mainly soft foods</p>

<p>&#8226;	Heartburn and chest pain are common EoE symptoms in adults</p>

<p>&lt;&lt;insert slide 7; Chapter Title: Click or tap here to enter text.; 04:16 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Diagnosis of EoE Is Challenging<sup>[4,5,7]</sup></strong></p>

<p>&#8226;	Just having eosinophils in the esophagus is not enough to make a diagnosis of EoE because this can be caused by other conditions </p>

<p>&lt;&lt;insert slide 8; Chapter Title: Click or tap here to enter text.; 05:28 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Endoscopic Findings</strong></p>

<p>&#8226;	Endoscopic findings in EoE can range from mild and subtle to very severe cases in which the entire esophagus becomes narrow and stiff like a drinking straw</p>

<p>&lt;&lt;insert slide 9; Chapter Title: <strong>Do PPIs Help With Diagnosis?</strong>; 06:30 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; The PPI Diagnostic Dilemma<sup>[1,5,8]</sup></strong></p>

<p>&#8226;	In recent years, data have shown that proton pump inhibitor (PPI) responsive EoE and EoE have very similar endoscopic and clinical findings</p>

<p>&#8226;	The aggregate of the data on PPIs and EoE indicates that PPIs are better used as a treatment for EoE than as a diagnostic tool</p>

<p><tt>o	</tt>International guidelines have removed PPI response as a diagnostic criteria for EoE</p>

<p>&lt;&lt;insert slide 10; Chapter Title: Click or tap here to enter text.; 08:36 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; The PPI Diagnostic Dilemma (cont)</strong></p>

<p>&lt;&lt;insert slide 11; Chapter Title: <strong>Treatment Overview</strong>; 09:34 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Treatment Goals<sup>[9]</sup></strong></p>

<p>&#8226;	<strong>Jonathan M. Spergel, MD, PhD:</strong> One of the biggest issues with EoE is that histologic response -- reduction in eosinophils in the esophagus -- often does not correlate well with symptom relief</p>

<p>&lt;&lt;insert slide 12; Chapter Title: Click or tap here to enter text.; 10:42 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Treatment Options for EoE<sup>[5,9]</sup></strong></p>

<p>&lt;&lt;insert slide 13; Chapter Title: Click or tap here to enter text.; 11:33 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; PPI Therapy<sup>[10,11]</sup></strong></p>

<p>&#8226;	PPI therapy for EoE should be high dose: 20 mg to 40 mg twice daily or equivalent in adults, and 1 to 2 mg/kg or equivalent in children</p>

<p>&lt;&lt;insert slide 14; Chapter Title: <strong>Steroids;</strong> 12:30 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Steroids for EoE: Overview<sup>[9,11]</sup></strong></p>

<p>&#8226;	Topical steroids are the mainstay of therapy for EoE; they are highly effective in eliminating eosinophils and improving symptoms</p>

<p>&#8226;	Most clinicians will start with an 8- to 12-week course of topical steroids and re-evaluate the patient after 6 to 12 weeks</p>

<p>&lt;&lt;insert slide 15; Chapter Title: Click or tap here to enter text.; 14:13 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Swallowed Topical Steroids<sup>[2,5]</sup></strong></p>

<p>&#8226;	It is essential to dose steroids properly in patients with EoE</p>

<p>&lt;&lt;insert slide 16; Chapter Title: Click or tap here to enter text.; 15:33 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Optimal Delivery of Topical Steroids<sup>[9]</sup></strong></p>

<p>&#8226;	Patients should receive specific instructions for both the preparation of the steroid and how to use it</p>

<p>&#8226;	There are many different ways to mix a swallowed steroid preparation; much of it comes down to patient preference</p>

<p>&lt;&lt;insert slide 17; Chapter Title: Click or tap here to enter text.; 16:32 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Budesonide: Nebulized vs Viscous Oral Formulations<sup>[12]</sup></strong></p>

<p>&#8226;	The better the steroid formulation coats the esophagus, the better the patient's response will be</p>

<p>&lt;&lt;insert slide 18; Chapter Title: Click or tap here to enter text.; 16:57 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Budesonide Oral Suspension: Phase 2 Trial<sup>[13]</sup></strong></p>

<p>&#8226;	In this phase 2 study of a novel budesonide oral suspension (BOS), symptoms measured by a standardized dysphagia symptom questionnaire were significantly improved in the BOS arm compared with placebo</p>

<p>&#8226;	Histologic response rates and endoscopic severity were also substantially improved in the BOS treatment arm</p>

<p>&lt;&lt;insert slide 19; Chapter Title: Click or tap here to enter text.; 18:18 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Budesonide Orodispersible Tablet: Phase 3 Trial<sup>[14]</sup></strong></p>

<p>&#8226;	A phase 3 trial done in Europe evaluated an dissolvable budesonide tablet for treatment of EoE</p>

<p>&#8226;	Whereas the BOS study was 12 weeks, this was a 6-week treatment course</p>

<p>&#8226;	No patients in the placebo arm had combined clinical-histologic remission vs 58% in the active treatment arm </p>

<p>&lt;&lt;insert slide 20; Chapter Title: Click or tap here to enter text.; 19:18 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Fluticasone Dissolvable Tablet: Phase 1/2A Study<sup>[15]</sup></strong></p>

<p>&lt;&lt;insert slide 21; Chapter Title: <strong>Diet Therapy</strong>; 19:51 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Elemental Diet<sup>[5,11,16]</sup></strong></p>

<p>&#8226;	The elemental diet is usually a last resort for EoE because the diet is so poorly tolerated</p>

<p>&lt;&lt;insert slide 22; Chapter Title: Click or tap here to enter text.; 20:47 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Elimination and Allergy-Directed Diets<sup>[16-19]</sup></strong></p>

<p>&#8226;	The efficacy of food elimination diets varies depending on the patient population and which foods are eliminated</p>

<p><tt>o	</tt>The 6-food elimination diet is approximately 50% to 70% effective</p>

<p>&#8226;	Food elimination diets have generally replaced allergy-directed diets for EoE because they are less complicated and just as effective</p>

<p>&lt;&lt;insert slide 23; Chapter Title: Click or tap here to enter text.; 22:20 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Step-Up/Step-Down Elimination Diets<sup>[18,20]</sup></strong></p>

<p>&#8226;	Step-up or step-down diets either add or eliminate potential food triggers one at a time</p>

<p>&#8226;	In most patients with EoE, milk is the number one trigger followed by eggs and wheat</p>

<p>&lt;&lt;insert slide 24; Chapter Title: Click or tap here to enter text.; 22:59 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Elimination Diets: Patient Education</strong></p>

<p>&#8226;	<strong>Dr Spergel: </strong>What I find most effective in my practice is to emphasize what patients can eat rather than what they cannot eat</p>

<p><tt>o	</tt>It is also very important to work with dieticians to help patients comply with diets and make sure patients are getting the proper nutrients</p>

<p>&lt;&lt;insert slide 25; Chapter Title: <strong>Biologics Under Investigation;</strong> 24:00 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; IL-5 Inhibitors<sup>[21-24]</sup></strong></p>

<p>&#8226;	Clinical studies of interleukin (IL) 5 inhibitors in EoE showed some efficacy in reducing eosinophilia, but not for improving symptoms</p>

<p>&lt;&lt;insert slide 26; Chapter Title: Click or tap here to enter text.; 24:55 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Dupilumab: Phase 2 Study<sup>[25]</sup></strong></p>

<p>&#8226;	In a phase 2 study of dupilumab, an anti-IL-4/IL-13 antibody, for EoE in adults, there were significant improvements in symptoms of dysphagia and in secondary endpoints vs placebo</p>

<p>&#8226;	This agent appears to show promise for treatment of EoE</p>

<p>&lt;&lt;insert slide 27; Chapter Title: Click or tap here to enter text.; 25:57 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Anti-IL-13 RPC4046: Phase 2 Study<sup>[26]</sup></strong></p>

<p>&#8226;	RPC4046 is another novel anti-IL-13 agent that has shown promise for EoE treatment</p>

<p>&#8226;	In a phase 2 study, patients who received this agent had significant improvement of EoE symptoms and endoscopic features compared with placebo</p>

<p>&#8226;	Symptoms improved significantly in the steroid-refractory population, which was of interest</p>

<p>&lt;&lt;insert slide 28; Chapter Title: <strong>Dilation Therapy</strong>; 27:08 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Endoscopic Dilation Therapy<sup>[5,27,28]</sup></strong></p>

<p>&#8226;	Dilation therapy is a purely mechanical treatment for EoE; the dilator is breaking up the scar tissue and fibrosis that has formed</p>

<p>&#8226;	It does not affect the underlying pathophysiology of the disease</p>

<p>&lt;&lt;insert slide 29; Chapter Title: Click or tap here to enter text.; 28:06 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Endoscopic Dilation Therapy (cont)<sup>[27-29]</sup></strong></p>

<p>&#8226;	The main side effect of dilation therapy is chest pain, which can last for several days and can be moderate to severe</p>

<p>&#8226;	It is important to explain to patients that chest pain after the procedure is expected and does not mean something has gone wrong</p>

<p>&lt;&lt;insert slide 30; Chapter Title: Click or tap here to enter text.; 29:36 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Endoscopic Dilation: Images<sup>[28]</sup></strong></p>

<p>&lt;&lt;insert slide 31; Chapter Title: <strong>Concluding Remarks</strong>; 30:59 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Concluding Remarks</strong></p>

<p>&#8226;	It is critical to get the correct diagnosis in EoE; this means having the full clinical and histologic picture and ruling out conditions that can mimic EoE</p>

<p>&#8226;	Dilation has an important role in treating strictures and keeping the esophagus open</p>

<p>&#8226;	If patients are not responding, make sure they are taking their medication correctly and/or implementing their diets correctly</p>

<p>&#8226;	There are many new therapies for EoE on the horizon, including new formulations of topical therapies and biologics</p>

<p>&lt;&lt;insert slide 32; Chapter Title: Click or tap here to enter text.; 32:56 &gt;&gt; </p>

<p><strong>&lt;&lt;Level 2&gt;&gt; Thank You</strong></p>